Abstract The international American Joint Committee on Cancer/Union for International
Cancer Control (AJCC/UICC) tumour-node-metastasis (TNM) staging system provides the …

The highly complex and heterogenous ecosystem of a tumour not only contains malignant
cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts …

Immunotherapy is currently the most rapidly advancing area of clinical oncology, and
provides the unprecedented opportunity to effectively treat, and even cure, several …

Background Patients with castration-resistant prostate cancer derive only modest clinical
benefit from available therapies. Blockade of the inhibitory programmed death 1 (PD-1) …

Background Advanced prostate cancer remains one of the most common and deadly
cancers, despite advances in treatment options. Immunotherapy has provided little benefit to …

Precursor states of multiple myeloma (MM) and its native tumor microenvironment need in-
depth molecular characterization to better stratify and treat patients at risk. Using single-cell …

Although common evolutionary principles drive the growth of cancer cells regardless of the
tissue of origin, the microenvironment in which tumours arise substantially differs across …

One in seven men in North America is expected to be diagnosed with prostate cancer (PCa)
during their lifetime (,). While a wide range of treatment options including surgery, radiation …

Background Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …

In the last decade, immunotherapy has revolutionized the treatment landscape of several
hematological and solid malignancies, reporting unprecedented response rates …